The Early Money
The Early Money
When Todd Zion began looking for funds to launch Smart-Cells, a new company developing self-regulating insulin-delivery systems for patients with diabetes, he needed to raise just shy of $1.25 million, a number that "doesn't even show up on the radar screens of big venture capital firms," he says.